INTRAVITREAL INJECTION OF THERAPEUTIC AGENTS
The DOI matches its Crossref record; 525 of the 536 references it cites were found in a registry or an index.
Abstract
In Brief Background: Intravitreal injection (IVI) with administration of various pharmacological agents is a mainstay of treatment in ophthalmology for endopthalmitis, viral retinitis, age-related macular degeneration, cystoid macular edema, diabetic retinopathy, uveitis, vascular occlusions, and retinal detachment. The indications and therapeutic agents are reviewed in this study. Methods: A search of the English, German, and Spanish language MEDLINE database was conducted. A total of 654 references spanning the period through early 2008 were individually evaluated. Results: The advantage of the IVI technique is the ability to maximize intraocular levels of medications and to avoid the toxicities associated with systemic treatment. Intravitreal injection has been used to deliver several types of pharmacological agents into the vitreous cavity: antiinfective and antiinflammatory medications, immunomodulators, anticancer agents, gas, antivascular endothelial growth factor, and several others. The goal of this review is to provide a detailed description of the properties of numerous therapeutic agents that can be delivered through IVI, potential complications of the technique, and recommendations to avoid side effects. Conclusion: The IVI technique is a valuable tool that can be tailored to the disease process of interest based on the pharmacological agent selected. This review provides the reader with a comprehensive summary of the IVI technique and its multitude of uses. Intravitreal injection has been used to deliver numerous pharmacological agents into the vitreous cavity: antiinfective and antiinflammatory medications, immunomodulators, antineoplastic agents, gas, antivascular endothelial growth factor, and others. In this review, we describe the properties of many intravitreal therapeutic agents, the technique of intravitreal injection, complications, recommendations to avoid side effects, and future trends.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although rates of intraocular inflammation related to intravitreal injection remain relatively low, the overall burden on patients remains a key concern with millions of injections performed every year [85].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [85]
Citations
Cites
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Promotion of microtubule assembly in vitro by taxol
SCHIFF, P. B., FANT, J., & HORWITZ, S. B. (1979) · Nature · doi:10.1038/277665a0 · Cited by 3,600
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Virus interference. I. the interferon
Isaacs, A., & Lindenmann, J. (1957) · Proceedings of the Royal Society of London. Series B - Biological Sciences · doi:10.1098/rspb.1957.0048 · Cited by 3,451
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
Effects of cytochalasin and phalloidin on actin.
Cooper, J. A. (1987) · The Journal of cell biology · doi:10.1083/jcb.105.4.1473 · Cited by 2,009
Guba, M., von Breitenbuch, P., Steinbauer, M., Koehl, G., Flegel, S., Hornung, M., Bruns, C. J., Zuelke, C., Farkas, S., Anthuber, M., et al. (2002) · Nature Medicine · doi:10.1038/nm0202-128 · Cited by 1,739
The tor pathway: a target for cancer therapy
Bjornsti, M.-A., & Houghton, P. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1362 · Cited by 1,314
Research works printed but not linked: 8
- Komoto, 1912, Ueber Glaskorperwaschung bei unheilbarer Glaskorperblutung., KIin Monatsbl Augenheilkd, 50, 265
- Lowenstein, 1912, Uber Glaskorperersatz: 1.Teil: Experimentelle Untersuchungen., Albrecht von Graefes Arch Ophthalmol, 80, 500
- Zirm, 1925, Ein Beitrag zur Glaskorperabsaugung., Klin Monatsbl Augenheilkd, 75, 730
- Kucers, 1979, The Use of Antibiotics: A Comprehensive Review with Clinical Emphasis. 3rd ed.
- Rosenfeld, 2006, Ranibizumab: phase III clinical trial results., Ophthalmol Clin North Am, 19, 361
- Case, 1985, Clearance of intravitreal 3H-fluorouracil., Ophthalmic Surg, 16, 378
- Pillat, 1956, The aging of the retina., Trans Am Acad Ophthalmol Otolaryngol, 60, 206
- Dominguez, 1985, Cirugia precoz y ambulatoria del desprendimento de retina. (Spanish)., Arch Soc Esp Oftalmol, 48, 47
Cited by
Items 201–258 of 258
Sezer, T., Altıkardeşler, E., Erdoğan, K., Arslan, B., & Çolak, K. (2025) · Therapeutic Advances in Ophthalmology · doi:10.1177/25158414241275360 · Cited by 1
Zabaneh, I. D., Dunn, T., Dunn, K., & Williams, P. D. (2026) · International Journal of Retina and Vitreous · doi:10.1186/s40942-026-00824-3 · Cited by 2
“Immunosuppressive conditions such as diabetes mellitus are also thought to increase risk of post IVI endophthalmitis [9].”
InfluentialDavid, D., Zur, D., Biran, A., Braudo, S., Brosh, K., Moisseiev, E., Shulman, S., Barak, Y., Ehrlich, R., Fried, S., et al. (2026) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-026-07285-2 · Cited by 1
Yahalomi, T., Achiron, A., Moscovici, D., Plopsky, G., Cohen, R., Braudo, S., Kaplanov, I., Katz, M., Arnon, R., & Pikkel, J. (2026) · International Ophthalmology · doi:10.1007/s10792-026-03961-8 · Cited by 1
Hovaghimian, D., & Adel, S. S. (2016) · Journal of the Egyptian Ophthalmological Society · doi:10.4103/2090-0686.202260 · Cited by 1
Foscarnet calcium microcrystals as the intravitreal drug depot
Sun, Y., Tao, Y. K., Cao, Q., & Huang, Y. (2017) · Chemical Communications · doi:10.1039/c7cc02399e · Cited by 1
The Effect of Intravitreal Injection on the Corneal Endothelium
Ryu, S. J., Shin, Y. U., Kang, M. H., Seong, M., & Cho, H. Y. (2017) · Journal of the Korean Ophthalmological Society · doi:10.3341/jkos.2017.58.4.401 · Cited by 1
Ocular Pain According to Needle Diameter during Intravitreal Injection
Lee, S., Kim, W. H., Kim, S. J., & Park, J. S. (2020) · Journal of the Korean Ophthalmological Society · doi:10.3341/jkos.2020.61.9.1042 · Cited by 1
Falavigna, L., Scheid, K. L., Lavinsky, D., & Mallmann, F. (2021) · Clinical & Biomedical Research · doi:10.22491/2357-9730.105451 · Cited by 1
Acute Retinal Necrosis in an Immunocompetent Patient Treated With Intravitreal Ganciclovir
Nashawi, M., Bahr, T. A., & Palmer, T. (2021) · Cureus · doi:10.7759/cureus.17816 · Cited by 1
“However, intravitreal injections remain a mainstay for utilization in the clinical context due to the benefit of maximizing the vitreal concentration of drugs, while mitigating systemic drug toxicity [15].”
BackgroundEffect of intravitreal injections on the progression and prognosis of primary open-angle glaucoma
Movsisyan, A. B., Геннадьевна, Г. Н., Brezhnev, A. Y., & Kuroyedov, А. V. (2021) · Russian Journal of Clinical Ophthalmology · doi:10.32364/2311-7729-2021-21-4-227-234 · Cited by 1
(2017) · Journal of Ocular Biology · doi:10.13188/2334-2838.1000028 · Cited by 1
Vardar, C., George‐Weinstein, M., Getts, R. C., & Byrne, M. E. (2024) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2024.0024 · Cited by 2
“7,8 There is a large unmet need and market for noninvasive drug delivery to the anterior and posterior segment.”
Development of novel laser processes for ophthalmology and dentistry
Góra, W. S. (2016) · Cited by 1
Tavakoli, S. (2021) · Helda - University of Helsinki Institutional Repository · Cited by 3
Effect Of Lidocaine Gel On Endophthalmitis Rates Following Intravitreal Injections
Leng, T., & Lad, E. M. (2011) · Investigative Ophthalmology & Visual Science
Self-citationGasparin, F. (2013) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2013.tde-24062013-153022 · Cited by 1
An Update on Intravitreal Injections for Macular Diseases
Chan, V. C. K., Liu, D. T., & Lam, D. S. C. (2012) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0b013e31823e5b72
Antimicrobial pharmacology and infections of the eye
Hindle, E. (2014) · International Journal of Ophthalmic Practice · doi:10.12968/ijop.2014.5.4.118
Aguiar, R. G. (2011) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.47.2011.tde-30052012-162044 · Cited by 1
REVIEW OF INTRAVITREAL IMPLANTS FOR EXTENDED DRUG DELIVERY TO THE POSTERIOR SEGMENT OF THE EYE
Haghjou, N., & Soheilian, M. (2011) · مجله چشمپزشکی بینا
India Ink Infiltration in Scleral Wounds After Intravitreal Injections
Perry, A. R. (2014) · International Journal of Ophthalmic Pathology · doi:10.4172/2324-8599.1000152
“Additionally, many physicians use topical antibiotics before and/or after the injection as an adjunct agent to reduce bacterial flora - although this remains controversial [1,10-13].”
BackgroundLiber, A. M. P. (2016) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.47.2016.tde-10052016-151624
Nanotechnology for Omics-Based Ocular Drug Delivery
Hirani, A., Grover, A., Lee, Y. W., Pathak, Y. V., & Sutariya, V. B. (2016) · IGI Global eBooks · doi:10.4018/978-1-5225-0549-5.ch013
Hirani, A. (2015) · VTechWorks (Virginia Tech)
Intravitreal Steroids for the Treatment of Macular Edema in Retinal Vein Occlusions
Zunz, E., & Loewenstein, A. (2015) · Springer eBooks · doi:10.1007/978-3-319-14487-0_6
Intravitreal drug administration for treatment of noninfectious uveitis
Yazıcı, A. (2015) · World Journal of Ophthalmology · doi:10.5318/wjo.v5.i3.125
Magnetic nanoparticles as intraocular drug delivery system to target Retinal Pigmented Epithelium
Giannaccini, M., Giannini, M., Calatayud, M. P., Goya, G. F., Cuschieri, A., Dente, L., & Vittoria, R. (2014) · CINECA IRIS Institutial research information system (University of Pisa)
Intravitreal injections: volume injected Vs. volume retained and its implications
Gupta, S. K., Kumar, A., & Sharma, A. K. (2018) · IP International Journal of Ocular Oncology and Oculoplasty · doi:10.18231/2581-5016.2018.0030
Intravitreal injections in veterinary ophthalmology: literature review
Андреевич, Б. С., Варёнова, Т., Varenova, T., & Германович, Ш. А. (2019) · Russian veterinary journal · doi:10.32416/article_5d10c406077651.53201157
Dexamethasone implant – An update
Biswas, J., & Pyare, R. (2020) · TNOA Journal of Ophthalmic Science and Research · doi:10.4103/tjosr.tjosr_75_20
Nanotechnology for Omics-Based Ocular Drug Delivery
Hirani, A., Grover, A., Lee, Y. W., Pathak, Y. V., & Sutariya, V. B. (2014) · Advances in chemical and materials engineering book series · doi:10.4018/978-1-4666-6363-3.ch008
Nanotechnology for Omics-Based Ocular Drug Delivery
Hirani, A., Grover, A., Lee, Y. W., Pathak, Y. V., & Sutariya, V. B. (2017) · IGI Global eBooks · doi:10.4018/978-1-5225-5195-9.ch017
(2014) · Journal of Ocular Biology · doi:10.13188/2334-2838.1000014
“Likewise, they are also increasingly employed to treat other types of CNV and macular edema of various etiologies [3-9].”
BackgroundPharmacotherapy of retinal diseases
(2022) · Elsevier eBooks · doi:10.1016/b978-0-12-819291-7.00025-3
Figurska, M. (2023) · Lekarz Wojskowy · doi:10.53301/lw/162024
Intravitreal injections in the context of incarcerated patients
Dzięgielewski, J., Barczak, I., Dalkowska, B., & Furga, A. (2023) · Probacja · doi:10.5604/01.3001.0054.1341
Vofo, B. N., Saada, M., Rivera, A., Cohen, S., Jaouni, T., & Khateb, S. (2024) · BMC Ophthalmology · doi:10.1186/s12886-024-03336-6
“Over the last two decades, there has been an exponential increase in the use of intravitreal injections of anti-vascular endothelial growth factors (VEGF) compounds in the management of a variety of retinal pathologies [1].”
BackgroundMoraes, E. C. D. S., Sobrinho, E. F. D. A., Gonçalves, B. Y., Amorim, R. J., Guimarães, G. F., Nascimento, K. C. C. G., da Silva, P. A. R. M., Maia, C. C., Neto, F. D. L., Coutinho, I. J. B., et al. (2024) · Journal of Advances in Medicine and Medical Research · doi:10.9734/jammr/2024/v36i45397
Cotto, H. A. M. (2024) · Digital Repository Service (Northeastern University) · doi:10.17760/d20659806
Tetsumoto, R., Matsumiya, W., Sotani, R., Kusuhara, S., & Nakamura, M. (2024) · Cureus · doi:10.7759/cureus.60356
“On the other hand, despite their known safety and tolerability, physicians must remain vigilant for any side effects following each intravitreal injection of anti-VEGF agents including biosimilars, even if they are infrequent [2].”
BackgroundInfluentialBoz, A. A. E., Kocamış, S. İ., Boncukçu, K. D., Kılıç, M. D., Sönmezoğlu, H. İ., & Çelik, E. (2024) · Ophthalmology Journal · doi:10.5603/oj.96736
“Intravitreal injection (IVI) has recently become the most common vitreoretinal procedure [1].”
Chen, K. Y., Chan, H.-C., & Chan, C. M. (2024) · Research Square · doi:10.21203/rs.3.rs-4740025/v1
Merkland, D., Viberg, A., Nilsson, M., Gustafson, P., & Fahnehjelm, K. T. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e38878
“Additionally, prophylactic intravitreal injections of therapeutic agents have been explored as an option for managing infections, although this approach requires further [26].”
BackgroundTrigeminal neuralgia after intravitreal injection
Sadeghi, E., Kim, E., & Chhablani, J. K. (2025) · Indian Journal of Ophthalmology - Case Reports · doi:10.4103/ijo.ijo_2353_24
Tessem, R. A., Dillon, A. B., Le, B., Hanson, J., Hui, M., Anderson, L., Tamhaney, A., Yu, F., Pettenkofer, M. S., & McCannel, T. A. (2025) · Cureus · doi:10.7759/cureus.89483
“IVI of pharmacological agents is a mainstay of treatment for common retinal pathologies, including age-related macular degeneration, vascular occlusions, diabetic retinopathy, endophthalmitis, and cystoid macular edema [13].”
Alswaina, N. F. (2025) · International Journal of Health Sciences · doi:10.25259/ojs_8923
Sagmeister, S. (2020) · Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.26745
Topical eye drug delivery hybrid nanoparticles with improved bioactivity and mucoadhesive properties
Duarte, C. D. M. (2022) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Assessing eIF4E-S209 Signaling and Translationally Regulated Mechanisms in Neurodegeneration
Tuccitto, M. A. (2023) · TSpace (University of Toronto)
Quadrant-Specific Pain in Intravitreal Injection: A Systematic Review and Meta-analysis
Sabaner, M. C., Gunes, I., Divarcı, A., Anguita, R., van Dijk, E. H. C., Desideri, L. F., Cehofski, L. J., & Subhi, Y. (2026) · Ophthalmology and Therapy · doi:10.1007/s40123-026-01342-z · Cited by 1
“Intravitreal injection (IVI) is among the most frequently performed ophthalmic procedures worldwide [1–3].”
Franz, M., Jairam, R. K., Ma, G., Rist, W., Fuchs, H., Kuepfer, L., Hanke, N., & Rimpelä, A. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c01877
Huang, C.-T., Wen, Y., Liu, P., & Tsai, R. (2026) · QJM · doi:10.1093/qjmed/hcag129
Automated Dose Adjustment for Intravitreal InjectionPreprint
Bateni, F., Zheng, Z., Zhang, L., Hu, G., & Kowsari, K. (2026) · Research Square · doi:10.21203/rs.3.rs-10284286/v1
Fenniri, I., & André, C. (2026) · Antibiotics · doi:10.3390/antibiotics15070710 · Cited by 1
“Standard intravitreal antibiotics are summarized in Table 4 [50,52,54–56].”
Norranitchaiyakul, A. (2026) · Journal of the Medical Association of Thailand · doi:10.35755/jmedassocthai.2026.8.02130
Pierre, M., Lamaa, D., Escriou, V., & Charrueau, C. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127392
Metadata
- Authors
- PEYMAN, G. A., LAD, E. M., & MOSHFEGHI, D. M.
- Affiliations
- University of Arizona (US)
- Stanford University (US)
- Corresponding author
- PEYMAN, GHOLAM A.
- Venue
- Retina
- Published
- 2009-07
- Volume
- 29
- Issue
- 7
- Pages
- 875-912
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W2090780299
- Cited by
- 255
- References
- 536
- Citations by year
- 2026: 11 · 2025: 12 · 2024: 24 · 2023: 15 · 2022: 12 · 2021: 11 · 2020: 15 · 2019: 15 · 2018: 11 · 2017: 19 · 2016: 24 · 2015: 16 · 2014: 18 · 2013: 11 · 2012: 20
- FWCI
- 2.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Retina (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Keywords
- intravitreal injection, endophthalmitis, viral retinitis, age-related macular degeneration, cystoid macular edema, diabetic retinopathy, uveitis, retinal detachment, VEGF inhibitors, anti-inflammatory agents, immunomodulators, anticancer agents, gas tamponade, injection complications
- MeSH terms
- Drug Therapy, Humans, Injections, Vitreous Body
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.